Sanofi $SNY Shares Acquired by NewEdge Wealth LLC

NewEdge Wealth LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 63.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,303 shares of the company’s stock after purchasing an additional 26,035 shares during the quarter. NewEdge Wealth LLC’s holdings in Sanofi were worth $3,298,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after buying an additional 1,869 shares during the period. AQR Capital Management LLC lifted its holdings in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after acquiring an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after acquiring an additional 752 shares during the period. Sivia Capital Partners LLC raised its position in shares of Sanofi by 5.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares during the period. Finally, Whittier Trust Co. raised its position in shares of Sanofi by 34.1% during the 2nd quarter. Whittier Trust Co. now owns 1,462 shares of the company’s stock worth $71,000 after purchasing an additional 372 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SNY. Citigroup started coverage on Sanofi in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. UBS Group reissued a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, TD Cowen restated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $62.67.

Sanofi Stock Down 1.3%

SNY stock opened at $46.76 on Friday. The firm’s 50-day moving average is $47.55 and its two-hundred day moving average is $48.55. The company has a market capitalization of $114.05 billion, a price-to-earnings ratio of 12.99, a price-to-earnings-growth ratio of 1.23 and a beta of 0.45. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.